Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using...

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• KRAS mutation testing in metastatic colorectal cancer (mCRC) using formalin-fixed, paraffin-embedded (FFPE) tissue is standard care.
• Existing molecular methods for KRAS mutation detection (exons 2, 3, 4) face limitations in sensitivity and speed.
• The clinical performance of the Idylla™ KRAS Mutation Test on FFPE samples from mCRC patients was evaluated.

Purpose of the Study:

• To assess the clinical performance and reliability of the Idylla™ KRAS Mutation Test.
• To compare the Idylla™ test with established KRAS mutation analysis methods.
• To determine the turnaround time and infrastructure requirements of the Idylla™ test.

Main Methods:

• Retrospective analysis of 182 FFPE tumor samples from mCRC patients.
• KRAS mutation analysis using the therascreen KRAS assay on RotorGene Q platform as a reference method.
• Comparison of results obtained from the Idylla™ KRAS Mutation Test and the reference method.
• Validation of discordant results using massive parallel sequencing or alternative routine approaches.

Main Results:

• High overall agreement (96.7%) between the Idylla™ KRAS Mutation Test and the reference method for mutation characterization.
• A low rate of true discordant results (3.3%, 6 out of 182 samples) was observed.
• The Idylla™ test demonstrated a turnaround time of two hours.

Conclusions:

• The Idylla™ KRAS Mutation Test provides a fast and reliable method for analyzing FFPE samples.
• The test requires minimal molecular infrastructure and expertise, facilitating its adoption.
• This test can effectively guide personalized treatment decisions for colorectal cancer patients.